Evidence map›Paper›PMID 32559370›Full record

ArticleACS chemical neuroscience2020

Different Inhibitors of Aβ42-Induced Toxicity Have Distinct Metal-Ion Dependency.

Ashley J Mason, Ian Hurst, Ravinder Malik, Ibrar Siddique, Inna Solomonov, Irit Sagi, Frank-Gerrit Klärner, Thomas Schrader, Gal Bitan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS chemical neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ashley J MasonDepartment of Neurology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095, United States.
Ian HurstDepartment of Neurology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095, United States.
Ravinder MalikDepartment of Neurology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095, United States.
Ibrar SiddiqueDepartment of Neurology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095, United States.
Inna SolomonovDepartment of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
Irit SagiDepartment of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
Frank-Gerrit KlärnerInstitute of Organic Chemistry, University of Duisburg-Essen, Essen 45117, Germany.
Thomas SchraderInstitute of Organic Chemistry, University of Duisburg-Essen, Essen 45117, Germany.ORCID 0000-0002-7003-6362
Gal BitanDepartment of Neurology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095, United States.ORCID 0000-0001-7046-3754

Funding

Misfolded protein-clearance enhancers for Alzheimer's therapyR01AG050721 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BITAN, GAL · 2015 to 2019
$2.0M
NIA NIH HHS R01 AG050721
6 · The paper itself

Abstract

Oligomers of amyloid β-protein (Aβ) are thought to be the proximal toxic agents initiating the neuropathologic process in Alzheimer's disease (AD). Therefore, targeting the self-assembly and oligomerization of Aβ has been an important strategy for designing AD therapeutics. In parallel, research into the metallobiology of AD has shown that Zn

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesHumansIonsPeptide FragmentsAmyloid beta-Peptidesamyloid beta-protein (1-42)IonsPeptide FragmentsaggregationAlzheimer’s diseaseAmyloidinhibitormetal ionsneurotoxicity

Identifiers

PMID32559370
PMCPMC7695034

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.